Marta Minervini
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Marta Minervini has a total of 2 co-authors. Here are the top co-authors by number of shared publications:
- Nadeen Y. Sarsour
University of Pittsburgh Department of Internal Medicine, Pittsburgh, PA
1 shared publication - Shahid Mahmud Malik
Division of Gastroenterology, Department of Medicine, Hepatology, and Nutrition, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA
1 shared publication
Latest Publications
- Open Access
- 1 April 2023
- Published by Wolters Kluwer Health in ACG Case Reports Journal
- Vol. 10 (4) , e01038
Cemiplimab-Associated Sinusoidal Obstruction Syndrome
A 58-year-old woman developed new-onset recurrent ascites after the recent initiation of cemiplimab for the treatment of advanced basal cell carcinoma. A comprehensive serological workup for viral, metabolic, and autoimmune causes was unrevealing. Transjugular liver biopsy demonstrated parenchymal changes consistent with a diagnosis of sinusoidal obstruction syndrome. While this is a condition commonly observed in patients after hematopoietic stem cell transplantation or use of chemotherapeutic agents, it should also be considered in patients who develop new-onset liver dysfunction after the initiation of checkpoint inhibitors.
- 1 April 2023
- Published by Wolters Kluwer Health in ACG Case Reports Journal
- Vol. 10 (4) , e01038
Open AccessCemiplimab-Associated Sinusoidal Obstruction Syndrome
A 58-year-old woman developed new-onset recurrent ascites after the recent initiation of cemiplimab for the treatment of advanced basal cell carcinoma. A comprehensive serological workup for viral, metabolic, and autoimmune causes was unrevealing. Transjugular liver biopsy demonstrated parenchymal changes consistent with a diagnosis of sinusoidal obstruction syndrome. While this is a condition commonly observed in patients after hematopoietic stem cell transplantation or use of chemotherapeutic agents, it should also be considered in patients who develop new-onset liver dysfunction after the initiation of checkpoint inhibitors.